Newer drugs and earlier treatment:  impact on lifetime cost of care for HIV-infected adults.
OBJECTIVE
To determine the component costs of care to optimize treatment with limited resources.


METHODS
We used the Cost-Effectiveness of Preventing AIDS Complications Model of HIV disease and treatment to project life expectancy and both undiscounted and discounted lifetime costs (2010 €).


METHODS
We determined medical resource utilization among HIV-infected adults followed from 1998 to 2005 in northern France. Monthly HIV costs were stratified by CD4 cell count. Costs of CD4, HIV RNA and genotype tests and antiretroviral therapy (ART) were derived from published literature. Model inputs from national data included mean age 38 years, mean initial CD4 cell count 372 cells/μl, ART initiation at CD4 cell counts less than 350 cells/μl, and ART regimen costs ranging from €760 to 2570 per month.


RESULTS
The model projected a mean undiscounted life expectancy of 26.5 years and a lifetime undiscounted cost of €535,000/patient (€320,700 discounted); 73% of costs were ART related. When patients presented to care with mean CD4 cell counts of 510 cells/μl and initiated ART at CD4 cell counts less than 500 cells/μl or HIV RNA more than 100,000 copies/ml, life expectancy was 27.4 years and costs increased 1-2%, to €546,700 (€324,500 discounted). When we assumed introducing generic drugs would result in a 50% decline in first-line ART costs, lifetime costs decreased 4-6%, to €514,200 (€302 ,800 discounted).


CONCLUSIONS
As HIV disease is treated earlier with more efficacious drugs, survival and thus costs of care will continue to increase. The availability in high-income countries of widely used antiretroviral drugs in generic form could reduce these costs.
ATIP-Avenir Inserm U, Université de Lille Nord de France, France.
Caroline E
CE
Sloan
Karen
K
Champenois
Philippe
P
Choisy
Elena
E
Losina
Rochelle P
RP
Walensky
Bruce R
BR
Schackman
Faiza
F
Ajana
Hugues
H
Melliez
A D
AD
Paltiel
Kenneth A
KA
Freedberg
Yazdan
Y
Yazdanpanah
D017088:AIDS-Related Opportunistic Infections / Q000191:economics* / Q000401:mortality / Q000517:prevention & control*; D000328:Adult; D019380:Anti-HIV Agents / Q000191:economics* / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D003362:Cost-Benefit Analysis; D019049:Developed Countries / Q000191:economics; D005260:Female; D005602:France / Q000453:epidemiology; D015658:HIV Infections / Q000188:drug therapy* / Q000191:economics* / Q000401:mortality; D017048:Health Care Costs; D006295:Health Resources / Q000191:economics; D006801:Humans; D008017:Life Expectancy; D008297:Male; D018803:Models, Economic; D018434:Sickness Impact Profile
D019380:Anti-HIV Agents